Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

EAST HANOVER, N.J., Aug. 13, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) accepted the company's supplemental Biologics License Application (sBLA) for a new self-administration option for Xolair® (omalizumab) across all approved US.

Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications

AbbVie

AstraZeneca

Johnson & Johnson

Eli Lilly

Merck

Pfizer

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

The digital press release with multimedia content can be accessed here:

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

Basel, August 4, 2020 — Novartis today announced positive results from the Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). At the interim analysis, the global study met its primary endpoint of complete response rate (CRR), as assessed by independent review committee. CRR is a standard measure of patient response to therapy in FL. No new Kymriah safety signals were observed. Results from the ELARA trial will be presented at an upcoming medical meeting and included in US and EU regulatory submissions.

Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma

Europe granted approval for Novartis drug Cosentyx in treating moderate-to-severe plaque psoriasis in patients age 6 to under 18, after successful Phase 3 testing, sending NVS stock rising.
The post Novartis Stock Lifted As Psoriasis Drug Notches EU Approval appeared first on Investor's Business Daily.

Novartis Stock Lifted As Psoriasis Drug Notches EU Approval

Basel, August 3, 2020 — Novartis, a leader in immuno-dermatology and rheumatology, today announced the European Commission (EC) has granted the approval for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to

Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis

Allogene Therapeutics Inc

Cellectis SA

Gilead Sciences

Tcr2 Therapeutics

Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

4 Companies That Could Upend the Pharma Industry

Bristol-Myers

Centene

Edwards Lifesciences

UnitedHealth Group

Last week, the Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the second quarter of the year.

The Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund

GlaxoSmithKline

Sanofi

As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.

5 High-Yield Drug Stocks That Are Undervalued With Great Upside

Basel, July 24, 2020 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization of Adakveo ®  (crizanlizumab) for the prevention of recurrent vaso-occlusive crises (VOCs), or pain crises, in patients with sickle cell disease aged 16 years and older. Adakveo can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.

Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease

With pantry-loading trends reversing, as well as weakness in some deferrable ophthalmology and dermatology products, growth has stalled in Q2.

Novartis Q2 Struck By Deferrable Portfolio Elements, But Pipeline Continues To Develop

Novartis AG's (NVS) CEO Vas Narasimhan on Q2 2020 Results - Earnings Call Transcript

The big drugmaker missed analysts' revenue and earnings estimates due to one primary reason.

What's Behind Novartis' Disappointing Q2 Results

Novartis' (NVS) second-quarter 2020 sales take a hit due to the coronavirus pandemic.

Novartis' (NVS) Q2 Earnings Surpass Estimates, Sales Miss

Novartis stock slipped in pre-market trading Tuesday after the drugmaker posted second-quarter sales that fell vs. a year-ago and missed analyst estimates, due to the coronavirus pandemic.

Novartis Stock Slips After Sales Miss Views On Coronavirus Impact

Novartis AG (SWX: NOVN) announced a significant decline in its sales and net profit in the second quarter on Tuesday. The company said that medicine stockpiling that was at its peak in the first quarter was largely reversed in Q2.

Novartis AG reports a 4% decline in net profit in the second quarter

Swiss drugmaker Novartis lowered its 2020 sales outlook on Tuesday after second quarter sales and profit fell, as hospitals that stocked up on medicines during the first-quarter due to the COVID-19 pandemic slowed purchases.

Novartis tightens outlook as second-quarter sales, profit fall

Basel, July 21, 2020 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said:  

Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

Basel, July 16, 2020 — Today, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause severe medical complications and can lead to death in some people, putting immense strain on fragile healthcare systems.

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Novartis (NVS) gets EC approval for Enerzair Breezhaler as a maintenance treatment for asthma.

Novartis Gets EC Approval for Enerzair Breezhaler for Asthma

T-Mobile US

Continental Resources

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Notable Insider Buys: Novartis, T-Mobile And More

The United States Department of Justice announced late on Wednesday that Novartis AG (ETR: NOT) will pay over £583.54 million to settle charges by the U.S. government that the Swiss drugmaker made illicit payments to patients and doctors in an unlawful attempt to push drug sales.

Novartis to pay over £583 million to settle U.S. charges of illicit incentives to doctors and patients

Novartis agreed to pay more than $729 million to settle U.S. government charges it paid illegal kickbacks to doctors and patients to boost drug sales, the U.S.

Novartis pays $729 million to settle U.S. kickback charges

Novartis AG (NYSE: NVS) has reached a $678 million settlement in a civil fraud lawsuit that alleged the company bribed doctors at speaker events it organized.

Novartis Settles $678M Fraud Lawsuit Alleging It Bribed Doctors At Company Speaker Events

Novartis AG has agreed to pay $678 million to settle a civil fraud lawsuit in which the U.S. government accused the Swiss drugmaker of illegally providing doctors with cash payments and other perks to induce them to prescribe its cardiovascular and diabetes drugs.

News for Novartis Stock (NVS)